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Lithium-induced reduction in urinary concentrating ability and
urinary aquaporin 2 (AQP2) excretion in healthy volunteers.
Background. Lithium therapy is associated with the develop-
ment of nephrogenic diabetes inspidus. Experimentally, lithium
inhibits arginine vasopressin (AVP)-stimulated translocation
of cytoplasmic aquaporin 2 (AQP2) to the apical membrane.
Clinically, the actions of lithium on renal tubular function are
less clearly established. This study examined the effects of four
weeks of lithium therapy on desmopressin (dDAVP)-stimulated
urinary concentrating ability in healthy volunteers.
Methods. Eleven healthy volunteers underwent baseline uri-
nary concentrating ability studies which were repeated follow-
ing 4 weeks therapy with lithium carbonate (250 mg twice
a day). Urinary osmolality, urinary AQP2 and cyclic adeno-
sine monophosphate (cAMP) levels were measured following
overnight fluid deprivation and after the administration of 40 lg
of dDAVP. Baseline values were compared with results after
4 weeks of lithium therapy.
Results. Four weeks of lithium therapy reduced dDAVP-
stimulated urinary concentrating ability (996 ± 27 to 945 ±
26 mOsm/kg) (P < 0.05) and this was associated with signifi-
cant reduction in urinary AQP2 excretion (99.2 ± 10.0 to 77.8 ±
7.4 fmol/lmol creatinine) (P < 0.05) and urinary cAMP excre-
tion (3188 ± 376 to 2212 ± 378 units) (P < 0.01).
Conclusion. Four weeks of lithium therapy in healthy vol-
unteers produced a small but significant reduction in dDAVP-
stimulated urinary concentrating ability, which appears to be
mediated by the inhibition of AVP-stimulated translocation of
cytoplasmic AQP2 to the collecting tubule apical membrane via
inhibition of adenyl cyclase.
Lithium therapy is a major therapeutic agent used to
treat patients with various mood disorders. However, it
has been associated with several different forms of re-
nal injury. In an analysis of several studies published
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from 1979 to 1986, comprising 1172 patients [1], the
most prevalent renal effect of lithium was impairment
of renal concentrating ability, which was estimated to
be present in at least 54% of 1105 unselected patients
on chronic lithium therapy. This defect translated into
overt polyuria and polydipsia in up to 20% of unselected
cases [1]. Initially, the decreased urinary concentrating
ability is largely reversible following cessation of lithium.
Of greater concern is the development of a progressive
impairment of urinary concentrating ability [nephrogenic
diabetes inspidus (NDI)] in patients on long-term main-
tenance lithium therapy, which is resistant to the actions
of arginine vasopressin (AVP) (antidiuretic hormone).
This functional lesion is not usually reversible and is as-
sociated with a chronic focal interstitial fibrosis in renal
biopsy [2, 3]. The lithium-induced interstitial fibrosis may
be progressive leading to end-stage renal failure [3].
The ability of the mammalian kidney to produce a con-
centrated urine is the function of two processes. First,
there is the creation of a hyperosmotic medullary intersti-
tium, and second there is the insertion of aquaporins into
the apical [aquaporin 2 (AQP2)] and basolateral mem-
branes (AQP3 and AQP4) of the collecting tubules to
allow the reabsorption of water down a concentration
gradient. Of these, AQP2, confined to the apical regions
of the principal cells of the collecting tubules, is the pri-
mary target for short-term regulation of collecting duct
permeability by the antidiuretic hormone (AVP) [4, 5].
Failure of such regulation, which may occur as a result
of a number of pathophysiologic conditions, leads to dis-
orders of water balance, manifest clinically by an inabil-
ity to concentrate the urine with associated nocturia and
polyuria [4, 5]. If not controlled, this has the ability to
further compromise renal function.
Lithium is likely to enter collecting duct cells via
the luminally located epithelial sodium channel (ENaC)
since this channel has a higher permeability for lithium
compared to sodium (reviewed in [6]). Once inside col-
lecting duct cells, lithium influences both sodium and
water handling pathways. Chronic lithium treatment in
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rats reduces amiloride-sensitive (ENaC) sodium current
and increases urinary sodium excretion [7]. This appears
to be due to down-regulation of ENaC subunit proteins
within the cells of the cortical and outer medullary col-
lecting duct [8]. A number of different mechanisms may
be involved in lithium-induced changes in tubular cell wa-
ter permeability. Briefly, lithium inhibits AVP-stimulated
translocation of cytoplasmic AQP2 to the apical mem-
brane. This may be due to lithium competing with mag-
nesium, inhibiting magnesium-dependent proteins that
activate AVP-sensitive adenyl cyclase [9]. AVP binds
to its V2 receptor stimulating adenyl cyclase and cyclic
adenosine monophosphate (cAMP) formation, which ac-
tivates protein kinase A. Protein kinase A phosphorylates
cytoplasmic AQP2, which is essential for its transloca-
tion and insertion into the apical membrane. Insertion
of AQP2 into the apical membrane then allows water
permeability and reabsorption in the cortical collecting
tubule. Failure of AQP2 insertion leads to an excess of
water delivered to the medullary tubule, which exceeds
the tubules capability to reabsorb water [4, 5]. The net
effect is polyuria.
Although there have been a number of experimental
studies investigating the actions of lithium, we report the
first study investigating the acute short-term (4 weeks)
effects of lithium therapy on urinary AQP excretion and
water concentrating ability in healthy volunteers. The
aim of this study was to measure the changes in AVP-
stimulated urinary concentrating ability and urinary AQP
excretion following 4 weeks of lithium carbonate therapy.
Baumgarten et al [10] have shown measurement of uri-
nary AQP2 excretion to be a useful approach to study
urinary concentrating defects and we have confirmed the
validity of urinary AQP measurement in response to wa-
ter deprivation and desmopressin (dDAVP) administra-
tion in normal volunteers [11].
METHODS
Eleven healthy volunteers (seven males and four fe-
males), with no known medical problems and taking no
medication, whose ages ranged from 20 to 63 years took
part in the study, after giving written informed consent.
The study was approved by the Otago Ethics Committee.
Participants’ demographic data are presented in Table 1.
Following baseline studies of urinary concentrating abil-
ity, each participant took lithium carbonate 250 mg twice
a day for 28 days. The urinary concentrating ability study
was then repeated.
Clinical studies
Following an overnight 12-hour fluid restriction, sub-
jects presented to the Clinical Research Area (Depart-
ment of Medicine). Height and weight was recorded.
Baseline blood samples for plasma osmolality, sodium,
creatinine, lithium, and AVP were taken. Baseline urine
Table 1. Demographics of participants
Age Mean 36.5 years (range 20–63 years)
Male:female 7:4
Plasma creatinine Mean 85 lmol/L (range 67–104 lmol/L)
Lithium concentrations at Mean 0.45 mmol/L (range 0.3–0.8 mmol/L)
completion of 4 weeks
was collected and analyzed for creatinine, AQP2, cAMP
levels, and osmolality. Subjects then received a standard
dose of 40 lg dDAVP (a synthetic analogue of AVP) in-
tranasally. Water intake was restricted to 500 mL over the
next 6 hours. All urine passed was collected and aliquots
analyzed for urinary creatinine, osmolality, AQP2, and
cAMP levels.
Plasma osmolality, creatinine, lithium, and sodium as
well as urinary osmolality and creatinine were mea-
sured by standard automated laboratory assays (Health-
lab Otago, Dunedin Hospital, New Zealand).
Urinary cAMP was assayed using a cAMP kit sup-
plied by BIOTRAK Assay System (code RPA 509; Amer-
sham Life Sciences, Sydney, Australia) and plasma AVP
was measured by an in-house radioimmunoassay [12]
(Endolab) (Christchurch Hospital, Christchurch, New
Zealand).
Urinary AQP2 levels were measured using a validated
chemiluminescent assay [11]. Briefly, 15 mL of urine was
spun (500 × g) for 10 minutes to remove cell debris
and the supernatant was then concentrated in a Cen-
triplus YM 10 (Amicon, Millipore, Bedford, MA, USA)
filter following the manufacturer’s instructions. Laemmli
loading buffer was added to the samples in the ratio of
2:1 and the samples denatured at 95◦C for 5 minutes.
Samples equivalent to 4 lmol urine creatinine were ap-
plied to membranes [Immobilon polyvinylidine difluo-
ride (PDVF) (Millipore, Bedford, MA, USA) in a BioDot
apparatus (Bio-Rad, Hercules, CA, USA). The mem-
branes were blocked for 1 hour in 5% nonfat dried milk in
Tris-buffered saline (TBS) [200 mmol/L Tris, 73 mmol/L
NaCl, pH 7.6, with 1% Tween 20 (vol/vol)]. After wash-
ing, the membranes were incubated overnight at 4◦C with
1:2500 dilution of rabbit antiserum raised against a syn-
thetic peptide made from the C- terminal end of human
AQP2 (amino acids 257-271 VELH-SPQALPRGTKA)
(Chiron Mimetopes, Melbourne, Australia). After fur-
ther washing, the membranes were incubated in the sec-
ondary antibody at 1:3000 dilution of goat antirabbit
IgG coupled to horseradish peroxidase (HRP) (DAKO,
PO488, Glostrup, Denmark). Antigen-antibody reac-
tions were detected by enhanced chemiluminescence
(Supersignal West Pico; Pierce, Rockford, IL, USA) ac-
cording to the protocol supplied by the manufacturer.
In order to quantitate the amounts of AQP2 in the
urine, synthetic peptide (Chiron Mimetopes, Melbourne)
was cross-linked to bovine serum albumin using a protein-
protein cross linking kit (P6305) (Molecular Probes,
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Fig. 1. Changes in urine osmolality. Responses to overnight water
deprivation and administration of desmopressin (dDAVP) (40 lg in-
tranasally) before and after 4 weeks lithium therapy in healthy volun-
teers (N = 11). Data mean ± SEM. ∗P < 0.05; ∗∗P < 0.01 compared to
0 weeks.
Eugene, OR, USA). Membranes were prepared as out-
lined above, with the cross-linked synthetic peptide used
as a standard. The resulting x-ray film was scanned den-
sitometrically (GS-700) (BioRad) and analyzed using
Molecular Analyst software. A standard curve (serial di-
lutions of the peptide) using the cross-linked protein ver-
sus densitometric readings was made. Urinary AQP2 lev-
els are expressed in terms of urinary creatinine levels.
Statistics
Values are mean ± SEM, R values and statistical values
were calculated with Kaleidograph (Synergy Software,
Reading, PA, USA).
RESULTS
All 11 subjects completed the study, with no reported
side effects. All subjects achieved a plasma lithium con-
centration that would be acceptable in standard clinical
practice (Table 1). Plasma lithium levels remained sta-
ble over the 4-week period (data not shown). The results
clearly demonstrate a significant reduction (P < 0.05) in
AVP-stimulated urine osmolality after 4 weeks of lithium
therapy (Fig. 1). Urine osmolality 4 hours post-dDAVP
fell from 996 ± 27 mOsm/kg to 945 ± 26 mOsm/kg (P <
0.05). The reduction in urinary concentrating ability was
associated with a significant reduction in AVP-stimulated
AQP2 excretion into the urine (Fig. 2). Urine APQ2
concentrations 4 hours post-dDAVP fell from 99.2 ±
10.0 fmol/lmol creatinine to 77.8 ± 7.4 fmol/lmol cre-
atinine, after 4 weeks of lithium therapy (P < 0.01).
In addition, there was a significant reduction in urinary
cAMP excretion (Fig. 3). Urinary cAMP excretion lev-
els at 4 hours post-dDAVP fell from 3188 ± 376 units
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Fig. 2. Changes in urine aquaporin 2 (AQP2) excretion. Response
to overnight water deprivation and administration of desmopressin
(dDAVP) (40 lg intranasally) before and after 4 weeks lithium ther-
apy in healthy volunteers (N = 11). Data mean ± SEM. ∗P < 0.05;
∗∗P < 0.01 compared to 0 weeks.
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Fig. 3. Changes in urine cyclic adenosine monophosphate (cAMP) ex-
cretion. Response to overnight water deprivation and administration of
desmopressin (dDAVP) (40 lg intranasally) before and after 4 weeks
lithium therapy in healthy volunteers (N = 11). Data mean ± SEM.
∗∗P < 0.01 compared to 0 weeks.
to 2212 ± 378 units (P < 0.01). The correlation between
urinary AQP2 concentrations and urinary cAMP concen-
tration was highly significant (r2 = 0.82).
The plasma AVP, osmolality, sodium, and creatinine
values were unchanged over the duration of the study
(Table 2).
DISCUSSION
This study has demonstrated that lithium carbonate
therapy significantly impairs urinary concentrating ability
within 4 weeks of initiating therapy in healthy volunteers.
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Table 2. Plasma measurements taken during the studies of urinary
concentrating ability at baseline and after 4 weeks of Lithium therapy
(N = 11)
0 hours 4 hours
Osmolality mOsm/kg
Baseline 288 ± 1 289 ± 1
4 weeks 289 ± 1 290 ± 1
Creatinine lmol/L
Baseline 85 ± 4 85 ± 4
4 weeks 90 ± 4 87 ± 4
Arginine vasopressin pmol/L
Baseline 2.19 ± 0.44 3.10 ± 0.69
4 weeks 3.05 ± 0.77 4.22 ± 0.55
Data mean ± SEM.
At the completion of 4 weeks of therapy, a 6% reduction
in urinary osmolality following 40 lg of intranasal dDAVP
was associated with a 27% reduction in urinary AQP2 ex-
cretion and a 44% reduction in urinary cAMP excretion.
The reduction in urinary cAMP excretion would support
the observation that lithium is inhibiting the pathway
whereby vasopressin leads to trafficking of AQP2 to the
apical membrane, as has been demonstrated experimen-
tally. Nielsen et al [4] has demonstrated in animal models
that lithium inhibits AVP-stimulated insertion of AQP2
into the apical membrane due to inhibition of adenyl cy-
clase which is normally activated following binding of
AVP to the V2 receptor.
Rats given lithium in the diet for 35 days, in amounts
calculated to be approximately equivalent to the thera-
peutic doasage in humans, became polydipsic and pro-
duced large volumes of dilute urine. AQP2 expression
in the kidneys of these rats was markedly reduced as as-
sessed by Western blotting [13, 14]. There was a parallel
decrease in AQP2 excretion in the urine, though a selec-
tive apical pathway [15]. It is likely that a similar situation
occurs in humans.
In the only reported study, investigating the actions
of lithium on urinary AQP2 excretion in humans, Ped-
ersen et al [16] recently demonstrated that a single dose
of lithium carbonate (600 mg) reduced the antidiuretic
effect of hypertonic saline up to 5 hours after ingestion.
They did not detect a significant change in urinary AQP2
excretion or urine output following an infusion of hyper-
tonic saline when compared to placebo. Unfortunately,
they did not measure urinary cAMP levels to support
their conclusion that an acute dose of lithium blunted the
antidiuretic effect associated with a hypertonic saline in-
fusion, by inhibiting trafficking of renal AQP2 in healthy
humans.
In this group of healthy individuals, the reduction in uri-
nary concentrating ability demonstrated in this short term
study, was not sufficient to produce partial NDI according
to standard criteria [17] as urinary concentrating ability
still exceeded 600 mOsm/kg. However, given the signifi-
cant changes that were evident even after a short course
of therapy, we would postulate that the impact of lithium
would become more apparent with time. The lithium-
induced changes in urinary concentrating ability tend to
become irreversible, however, the point at which this oc-
curs is currently unknown. It is also not clear if the defect
in humans is due solely to alterations in lithium-induced
inhibition of AVP-stimulated trafficking of AQP2 to the
apical membrane in the principal cells of the collecting
tubule. Further clinical studies are clearly required to an-
swer these important questions.
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